BIOMONITORING STUDY

Utah Statewide Investigation of Neonatal Blood Cadmium Levels Using Newborn Blood Spot Specimens

October 20, 2014

Prepared by the

Utah Department of Health
Division of Disease Control and Prevention
Bureau of Epidemiology
Environmental Epidemiology Program
TABLE OF CONTENTS

ACKNOWLEDGMENT ................................................................................................................................. 3
EXECUTIVE SUMMARY ............................................................................................................................ 4
INTRODUCTION ........................................................................................................................................... 5
DATA AND METHODS ............................................................................................................................... 8
FINDINGS .................................................................................................................................................. 10
DISCUSSION .............................................................................................................................................. 11
CONCLUSIONS AND RECOMMENDATIONS ......................................................................................... 14
AUTHORSHIP, REVIEW AND CITATION ............................................................................................. 16
CERTIFICATION ....................................................................................................................................... 17
REFERENCES ............................................................................................................................................. 18
TABLES AND FIGURES .......................................................................................................................... 26
DEFINITIONS ............................................................................................................................................. 29
DESCRIPTION OF LABORATORY METHODS ......................................................................................... 32
ACKNOWLEDGMENT

This investigation is a biomonitoring demonstration project for the Utah Environmental Public Health Tracking Network (UEPHTN). The UEPHTN is funded by a grant from the Centers for Disease Control and Prevention (CDC), Environmental Public Health Tracking Branch. The current UEPHTN award numbers are U50CCU822437, 1U38EH000954, and 5U38EH000182 (UEPHTN 2012).
EXECUTIVE SUMMARY

Cadmium poisoning has been recognized as a serious threat to public health for many years. In Utah, health care providers screen children based on clinical history and symptoms. Pregnant women and newborns are not routinely screened. Elevated blood cadmium levels can cause several adverse health effects including impaired neurological development.

This pilot project investigated the use of newborn blood spots as a sample media to conduct surveillance for blood cadmium in newborn infants. Two thousand, seven hundred and six (2,706) randomly selected blood spot cards submitted to the Utah Public Health Laboratory for the 2009 birth cohort were analyzed for blood cadmium levels. From each card, a sample of the blood spot and a sample of a blood-free area of the card were digested and analyzed for cadmium using inductively coupled plasma mass spectrometry. Quality control samples were analyzed with every batch of blood spot samples to assure laboratory data quality. The difference between the amount of cadmium in the blood spot and the amount of cadmium in the blood-free area of the card was considered to be the child’s blood cadmium level. After rejecting results for administrative recording errors or because the blood-free area of the card was contaminated with more cadmium than the blood spot (resulting in a negative value difference), the results for 1,404 Utah newborns were aggregated and evaluated at the county level. The geometric mean for the state was 0.10 µg/L (maximum = 8.64 µg/L). Two children were found to have blood cadmium levels ≥ 5.00 µg/L. However, this finding is based on a testing methodology that has not been validated and the estimates of performance were less than ideal. The Environmental Epidemiology Program does not recommend any change to current public health action or policy related to blood cadmium surveillance based on these results.

Biomonitoring is being explored nationally as a better way to understand the true exposure people experience which may contribute to adverse health effects. Before neonatal blood spots can be used as a routine screening media, additional work needs to be conducted to determine the sensitivity, specificity, and predictive value positive of this testing methodology. Prior to any decision leading to implementing this testing methodology as part of Utah’s current public health surveillance activities, consideration with respect to cost, alternative methods, and case follow-up should occur.
INTRODUCTION

What is Cadmium? Cadmium (\textit{Cd}) is a transition metal similar to zinc and mercury. Cadmium makes up about 0.1 ppm of the Earth's crust, and is found naturally in small quantities in air, water, and soil. In water, cadmium tends to sequester into the sediment layers under bodies of water. Because of its geochemical similarities, cadmium is often associated with zinc, lead, and copper ores. As a consequence, cadmium is produced mainly as a byproduct from mining, smelting, and refining sulfidic ores of zinc, and, to a lesser degree, lead and copper. The most common and industrially important form of natural cadmium is greencockite (CdS), which is nearly always associated with sphalerite (ZnS) (ATSDR 2012; EPA 2000; IPCS 2010).

Cadmium has many common industrial uses. The most important is in the nickel-cadmium rechargeable battery. Cadmium is used also to manufacture other electronic components, cadmium-based pigments and coatings, stabilizers in plastic production, and is commonly used in electroplating as an anti-corrosion agent (ATSDR 2012; EPA 2000; ICA 2014; IPCS 2010; Jarup 2003).

There is no significant recycling program for cadmium, and cadmium is released into the environment by incineration of household or industrial wastes, coal, and petroleum fuels. The smelting of zinc, lead, and copper ore also releases cadmium into the environment. Higher levels of cadmium are often found in surface soils and waters near smelters, incinerators, industrial areas, and hazardous waste sites. More than a third of all the superfund sites in the United States are contaminated with cadmium (ATSDR 2012; EPA 2000; ICA 2014; IPCS 2010).

Cadmium Exposure: Cigarette smoking is considered the most significant source of exposure for cadmium. Inhalation due to industrial emissions can be a significant exposure route for people who live in close proximity to the sources. Cadmium exposure may also occur as a result of ingesting contaminated food or water. Because of the high rates of soil-to-plant transfer, cadmium is a contaminant found in most plant-based foods. Thus diet is the most important source for cadmium exposure among non-smokers. Some dietary supplements are known to be a source (Bernhoft 2013; Bertin & Averbeck 2006; IPCS 2010; Guan et al. 2010; Hinwood et al. 2013; Jarup 2003; Satarug & Moore 2004; Satarug et al. 2009; Thompson et al. 2008).

Cadmium sequesters in the liver and kidney and has a 25-year half-life. Cadmium in the blood has a 75-day half-life on average. For adults, blood is not considered a good biological medium for measuring acute cadmium exposure (Bernhoft 2013).

Cadmium Toxicity: The toxicity of acute high-dose exposure to cadmium has been known since 1858 (Norberg 2009). Low-level chronic exposure to cadmium was found to be associated with a painful condition known as Itai-itai disease in Japan in 1957 (Bertin & Averbeck 2006; Norberg 2009).

Cadmium induces tissue damage through oxidative stress, leading to epigenetic changes in DNA expression and cellular and physiologic dysfunction (Bernhoft 2013; Bertin & Averbeck 2006; Filipic 2012; Fowler 2009; IPCS 2010; Jarup 2003; Joseph 2009; Mendez-Armenta & Rios 2007; Norberg 2009; Satarug & Moore 2004; Waisberg et al. 2003). Cadmium also interferes
with DNA repair (Bertin & Averbeck 2006; Filipic 2012; Giaginis et al. 2006; Waisberg et al. 2003). These two mechanisms of harm form the basis for cadmium toxicity and carcinogenicity. Because cadmium in the blood sequesters into kidney tissue, cadmium is particularly toxic to the kidneys. Other systems affected by cadmium toxicity include the neurologic system, the cardiovascular system, the immune system, the reproductive system, and bone tissue (Bernhoft 2013; Bertin & Averbeck 2006; Filipic 2012; Fowler 2009; IPCS 2010; Jarup 2003; Mendez-Armenta & Rios 2007; Norberg 2009; Satarug & Moore 2004; Thompson et al. 2008). Cadmium exposure is a known risk factor for developing insulin resistance (Bernhoft 2013). Exposure to cadmium in men has been shown to decrease lung function (Oh et al. 2014).

Children with low-level environmental cadmium exposure may have a higher risk for attention deficit hyperactivity disorder (ADHD) and learning disabilities (Ciesielski et al. 2012; Wang & Du 2013). However, not all researchers were able to find this effect (Kim et al. 2013). Female children have a higher risk for learning disabilities from cadmium exposure than male children (Llop et al. 2013).

Cadmium is considered to be carcinogenic and is linked to breast, prostate, renal, lung, and pancreatic cancers, as well as non-Hodgkin lymphoma (Bernhoft 2013; Fowler 2009; Guan et al. 2010; IARC 1993; Jarup 2003; Joseph 2009; Satarug & Moore 2004; Waalkes 2003; Waisberg et al. 2003).

**Maternal and Fetal Cadmium Exposure**: Cadmium affects both maternal and fetal health (Hinwood et al. 2013). Maternal exposure to cadmium results in bioaccumulation of cadmium in the placenta tissue. The level of cadmium in the placenta can be several times higher than the maternal blood cadmium level (Esteban-Vasallo et al. 2012; Kippler et al. 2010; Kuhnert et al. 1982; Lin et al. 2010). The placenta acts as a partial barrier to fetal exposure to cadmium from the mother (Caserta et al. 2013; Esteban-Vasallo et al. 2012; Garcia-Esquinas et al. 2013; Gundacker & Hengstschlager 2012; Lauwerys et al. 1978; Lin et al. 2010).

Placental cadmium interrupts the transportation of micronutrients to the fetus, resulting in delayed fetal development and low birth weight (Casterta et al. 2013; Garcia-Esquinas et al. 2013; Gundacker & Hengstschlager 2012; Kippler et al. 2010; Lin et al. 2010; Menai et al. 2012; Ronco et al. 2009; Sun et al. 2014; Thompson et al. 2008). Cadmium can act as a metalloestrogen and an endocrine disrupter that deregulates fetal development (Henson et al. 2004; Kawai et al. 2002; Stasenko et al. 2010; Thompson et al. 2008). The effects of perinatal developmental delays can persist for the first several years of the child's life (Lin et al. 2010). Cadmium has also been found to pass from nursing mothers to their infants in the breast milk (Satarug & Moore 2004).

There is a strong correlation between smoking and maternal blood cadmium levels, placental bioaccumulation of cadmium, and fetal cadmium levels. Smoking results in dramatic increases in the cadmium levels of the placenta and fetus. Maternal smoking cessation is the most important preventive action that can be taken to protect the fetus from exposure to cadmium (Esteban-Vasallo et al. 2012; Falcon et al. 2002; Garcia-Esquinas et al. 2013; Kuhnert et al. 1982; Kutlu et al. 2006; Menai et al. 2012; Sikorski et al. 1988; Sun et al. 2014; Thompson et al. 2008). Maternal cadmium levels are lowered by iron and folic acid nutritional supplement intake.
(Hinwood et al. 2013). The appropriate intake of dietary iron will also help reduce blood cadmium levels in children (Silver et al. 2013).

**Reference Dose and National Exposure Levels:** The U.S. Environmental Protection Agency (EPA) has not established a reference dose (RfD) for cadmium (EPA 1987, 2000; Taylor et al. 2014). Without a reference dose it is not possible to establish an elevated blood cadmium level (EBCL) equivalent.

Based on the 1999-2000 National Health and Nutrition Examination Survey (NHANES), a cross-sectional survey of the non-institutionalized U.S. population, the geometric mean total blood cadmium concentration among women of childbearing age was 0.38 µg/L (1.80 µg/L maximum) (CDC 2009; Sanders et al. 2012). Some countries have set RfD values from which a blood reference dose can be calculated (Al-Saleh et al. 2011; Taylor et al. 2014). For example, in Germany the equivalent RfD for blood is 0.50 µg/L (Al-Saleh et al. 2011; Wilhelm et al. 2006). The Agency for Toxic Substances and Disease Registry (ATSDR) uses the guidance set by the American Conference of Governmental Industrial Hygienists (ACGIH), which is 5.00 µg/L (ATSDR 2012). This value has also been used by other investigators in the United States (Garcia-Esquinas et al. 2013; McKelvey et al. 2007).

**Rocky Mountain Biomonitoring Consortium and the Utah Environmental Public Health Tracking Network Biomonitoring Initiatives:** In 2001, the Centers for Disease Control and Prevention (CDC) established the National Biomonitoring Program within its Division of Laboratory Sciences (APHL 2009, CDC 2008). Concurrent with that action, CDC awarded pilot money for state laboratory biomonitoring to develop and propose demonstration projects. At that time, the Utah Public Health Laboratory (UPHL) joined with the state laboratories of Arizona, Colorado, Montana, New Mexico, and Wyoming to form the Rocky Mountain Biomonitoring Consortium (RMBC). The RMBC had a number of goals, one of which was to explore the ability of each state’s laboratory to specialize in some of the laboratory service requirements and provide those services to the other states in the RMBC. The consortium identified and proposed nine demonstration projects, one of which was to use neonatal blood spots to conduct heavy metals biomonitoring. In 2003, the RMBC became one of three grantees to receive funding to implement their proposed demonstration projects (APHL 2009). With that support, the UPHL developed laboratory methodology and capacity to analyze neonatal blood spots for lead, mercury, and cadmium (Chaudhuri et al. 2009).

In 2003, the Environmental Epidemiology Program (EEP) within the Utah Department of Health (UDOH) was awarded funding to start developing the Utah Environmental Public Health Tracking Network (UEPHTN) (UEPHTN 2013). In collaboration with the RMBC, the UEPHTN acquired money specifically to conduct a biomonitoring demonstration project. The UEPHTN received supplemental funding to conduct neonatal blood spot monitoring in 2009, and again in 2012 and 2013. With that supplemental funding, the UEPHTN contracted with the UPHL to randomly select and test blood spots for cadmium from the 2009 birth cohort. These cohorts were selected because they were available for testing.

**Report Objectives:** This report presents a statistical review of laboratory results provided by the UPHL to the EEP for newborn blood spot testing for cadmium. The primary purpose of this
review is to develop an understanding of the geographic distribution of epidemiologic risk associated with EBCL among the newborn population in Utah. A secondary purpose is to consider the utility of blood spot biomonitoring for conducting prospective blood cadmium surveillance.

**Authority and Funding:** This study was conducted as part of the UDOH Executive Director’s responsibility to investigate public health concerns within Utah. The executive director delegates responsibility for environmental health investigations to the EEP. Biomonitoring, population, and geographic data for this investigation are collected, maintained, and made available by the UEPHTN. The UEPHTN also funds the SAS® and ArcGIS® analytical software application licenses that were used to conduct this investigation. The UEPHTN is funded by a grant from the CDC (UEPHTN 2013). Personnel time used to conduct this investigation was charged against state-funded Environmental Health Administrative funds.

**Institutional Review Board:** This investigation was reviewed and approved by the UDOH Institutional Review Board (IRB) on March 20, 2007 (IRB #151) for analysis of the 2007 birth cohort. An additional IRB approved an expansion of the project to include samples from the 2008 and 2009 birth cohorts issued on January 11, 2012 (IRB #330). The purpose of this investigation was to gain an understanding of the geographic distribution of blood cadmium levels (BCL) and to explore the feasibility of using blood spots as a convenience sample for blood cadmium surveillance. The study protocol presented to the IRB did not allow the UPHL or EEP to have identifiable data for the infants whose blood spots were used in this investigation, nor did the study protocol include procedures for informing caretakers of infants with EBCL about the laboratory findings. The use of blood spots for this kind of surveillance is new and information about the reliability of the results and the use of those results in guiding patient care and treatment is known.

**DATA AND METHODS**

**Study Design:** This investigation is a retrospective statistical review of biomonitoring results for neonatal BCL among Utah newborns. However, statistical reviews lack the power to link EBCL incidence to putative risk factors (Jekel et al. 1996; Mann 2003). A statistical review is a tool used by the EEP to better understand the health status of a population, identify priorities for public health action, and assess public health activities.

This investigation funded biomonitoring of infants born in Utah by testing randomly selected blood spot cards by the UPHL. The Newborn Screening Program (NSP) maintains custody of all blood spots submitted to the UPHL and randomly selected 2,706 cards from the 2009 birth year cohort. These cards represent five percent of the total number (53,750) of children born in Utah during that year. This sample size is the result of funding and not based on the expected prevalence or a sample size and power calculation. After UPHL analyzed the cards for heavy metals, the results were submitted to the EEP for statistical analysis. The EEP evaluated the quality of the results and analyzed the data by county of residence.
**Blood Spot Analysis:** A detailed description is contained in the “Description of Laboratory Methodology” section later in this report. Briefly, two paper punches, called “dots”, were taken: one from the blood spot area and one from the blood-free area of each blood spot specimen card. The blood-free area punches were used to determine the level of heavy metal contamination on the paper.

Heavy metals from each dot were extracted using an acid digestion, and the clarified extract was analyzed for cadmium by inductively coupled plasma mass spectrometry (ICP-MS) (Chaudhuri et al. 2009).

**Vital Records Birth Data:** Vital records birth data were obtained from the Office of Vital Records and Statistics, UDOH. These data are standardized and made available through the UEPHTN (UEPHTN 2013). Vital birth records were used to quantify the total births occurring in Utah by county during 2009. Records of birth with maternal addresses outside of Utah or of undetermined sex were excluded from the tabulation.

**Blood Spot Sampling Data:** Two thousand seven hundred and six (2,706) samples were randomly drawn from all newborn blood spots collected from Utah children born during 2009, and were analyzed for whole-blood total cadmium. Data regarding the child’s sex and mother’s residential ZIP code were obtained from the NSP. When the UPHL received the cards, they were given an additional sample identification number specific to this project. The EEP was provided with only de-identified data that consisted of the project-specific sample identification number, and the child’s birth year, sex, and ZIP code information. One thousand two hundred and ninety-three (1,293; 47.8%) blood spot samples were from female infants and 1,423 (52.2%) samples were from male infants. The analytical result for each sample was geo-referenced to the mother’s county of residency using the ZIP code provided to the lab with the blood spot. Seventeen samples lacked a ZIP code and could not be geo-referenced to a Utah county. These samples were excluded from the final analysis.

Each infant’s BCL was calculated as the difference between the cadmium level measured in the blood spot minus the cadmium level for the paper blank from the same blood spot card (Funk et al. 2013). Three hundred and forty-seven (347) cards (13% of the cards) were tested multiple times as part of the laboratory quality control process or to confirm elevated results. The average difference between the lowest and highest calculated cadmium levels from a single card was 0.78 µg/L (standard deviation [SD] = 3.69 µg/L, maximum difference = 52.30 µg/L).

Cards with a paper blank cadmium level higher than the blood spot cadmium level, resulting in a negative value calculated BCL, were not included in the final analysis. One thousand two hundred and eight-five (1,285; 47.5%) cards were excluded because the paper blank had a higher cadmium reading than the blood spot. The lowest positive calculated BCL for cards with multiple tests was used for the final analysis. The 1,302 (48.1%) cards excluded from final analysis included 17 cards missing administrative (ZIP code) data and 1,285 cards with negative calculated BCLs. After exclusion, 1,404 cards were analyzed for county level geometric mean BCL and for EBCL frequency.
The t-test was used to determine whether there were differences in the calculated BCLs between female and male children. The mean of the log-transformed cadmium levels was -2.24 (SD = 1.33) for females and -2.36 (SD = 1.30) for males. The test for equality of variance (F = 1.05 with 679 degrees of freedom, and the p-value = 0.53) suggested that the variances between female and male results were not statistically different. The pooled t-test suggested that there was no difference in the distribution of calculated BCLs for females and males (t-value = 1.71 with 1,393 degrees of freedom, and the p-value of the null hypothesis = 0.09). Therefore, the results of female and male children were pooled for the final analysis.

Data Analysis: After aggregating by sex, birth cohort, county, and state groupings, the geometric mean and highest computed cadmium level were used to summarize the data. The geometric mean is the preferred measure of central tendency when the data are highly skewed toward and bounded by zero. As discussed above, the number of children born with cadmium levels above the current ACGIH RfD for elevated blood cadmium (5.00 µg/L) was tabulated.

FINDINGS

For the 1,404 Utah newborns included in the final analysis of this investigation, the geometric mean BCL was 0.10 µg/L (range = 0.00 to 8.64 µg/L). These 1,404 children represent approximately 2.6% of the 53,750 children born in Utah in 2009. The geometric mean and maximum BCLs tabulated by sex and county are presented in Tables 1 and 2, respectively. The county was determined by the maternal residential ZIP code at the time of birth. There is no available information about the residential tenure of the mothers.

Two (2) newborns were identified with EBCLs ≥ 5.00 µg/L, with blood cadmium levels of 6.91 and 8.64 µg/L. These children were located in Duchesne and Grand counties. Based on this count, the rate of children with EBCLs would be approximately 1.42 children per 1,000 births using the current ACGIH RfD. Utah has approximately 53,000 births per year based on the number of births per year between 2007 and 2012 (UDOH 2013). These findings suggest that approximately 76 children could be born each year with EBCLs ≥ 5.00 µg/L. However, this testing methodology was not validated with a gold standard screening method, and no conclusions should be made that lead to a public health action or policy change based on these results. In addition, there is no information regarding what level of cadmium should be considered elevated for children.

Validation of the blood spot results using paired venous blood samples from the infants would be necessary to assess the epidemiologic performance measures (specificity, sensitivity, and predictive values) used in evaluating screening methodology. Because this project relied on the availability of stored blood spots, this was not possible, and the true specificity and sensitivity of the blood spot testing methodology cannot be determined. The UPHL has a policy that when an elevated cadmium value is detected, the sample is automatically confirmed by analysis of a replicate punch from the same blood spot. In this study, 13% of the cards (349 of 2,706 cards) were reanalyzed to confirm high cadmium concentrations. By categorizing the relationship of the lowest and highest positive test value with respect to whether the child represented by the card had an EBCL (≥5.00 µg/L), the specificity was estimated to be 97% and the predictive value
positive was estimated to be 40%. The sensitivity could not be estimated using this approach (German 2000). The mean difference between the lowest and highest test for the cards was 0.8 µg/L (maximum difference = 52.30 µg/L, standard deviation = 3.69 µg/L). This estimation of epidemiologic predictive value positive was low indicating that the testing methodology does not perform well as a surveillance tool.

County data are presented geographically in Figure 1 and Table 2. The distributions of samples taken represented between 0.8% (Beaver County) and 30.0% (Grand County) of the children born per county during the project sampling period. The geometric mean ranged between 0.02 µg/L (Garfield County) and 0.22 µg/L (Duchesne and Wasatch counties). Although samples were taken for children born to Wayne county mothers, they were among those excluded and no Wayne County samples were analyzed. The summary statistics for Beaver, Daggett, and Rich counties are computed on two or less samples and are provided with the caution that the results are not stable.

**DISCUSSION**

**Public Health Surveillance (Why Do Biomonitoring?):** Health is one of the most important assets a human being is given. It permits each person to fully develop their capacities, thus allowing them to enjoy the highest quality of life. The mission of public health is to promote and protect people’s health through ten essential public health services (Harrell and Baker 1994; IOM 1988). The first of these services is to “monitor health status to identify community health problems” (Stanbury et al. 2012). Public health surveillance is the systematic, ongoing, population-based collection of data that leads to early detection and response to public health concerns (Choi 1998; Thacker et al. 1996). This service helps public health officials and policymakers identify and assess communities with public health challenges; define public health priorities; develop and implement informed public health policy; monitor and evaluate public health actions; discover knowledge about public health concerns; and guide public health outreach, education, and intervention activities (Dicker 2002; Stanbury et al. 2012; Thacker 2000; Thacker et al. 2012). To conduct public health surveillance, environmental epidemiology collects data about environmental hazards, exposure, and adverse health outcomes (Malecki et al. 2008; Thacker et al. 1996).

Health outcomes (e.g., disease, disability, death, etc.) surveillance is the collection and registration of “cases.” Ascertainment of cases is dependent on the willingness and timing of people seeking medical assistance and the capacity of health care to report conditions. This surveillance process has the advantage of involving the health care system, which is much larger and has more direct contact with people than public health agencies. The cost of health care registries varies depending on the level of active versus passive surveillance and the degree of additional data collection through abstraction or other linkages that occurs as part of the surveillance process. A drawback of health outcomes surveillance is that knowledge of cases is after the fact and the focus tends to be curative rather than preventive (Aldrich and Griffith 1993; Thacker et al. 1996).
Exposure surveillance, also called biomonitoring, is the monitoring of individual members of the population for the presence of an environmental agent or its subclinical or preclinical effects. Biomonitoring may occur in conjunction with health outcome surveillance (i.e., a child presents with symptoms of EBCL and is tested) or may occur by sampling otherwise healthy people (i.e., a child is tested as part of a screening requirement) (Albertini et al. 2006; Angerer et al. 2007; Thacker et al. 1996). Sampling usually involves collection of biological specimens (blood, urine, milk, saliva, hair, adipose, or other tissues) during a health care event (i.e., a routine physical) or through soliciting volunteers (Farmer et al. 1996; Needham et al. 2007). Biomonitoring has proven to be more costly and more difficult than health outcome or hazards surveillance.

Hazards surveillance is the identification and characterization of environmental sources of hazardous material such as cadmium (i.e., factories that discharge cadmium into the atmosphere). Because of the cost and difficulty of obtaining samples, many investigations model exposure from hazards surveillance data rather than conducting exposure surveillance (Angerer et al. 2007). An advantage of biomonitoring is that these data provide a better understanding of exposure in the diseased and healthy populations. This concept is important in understanding thresholds (i.e., a dose-response curve) that contribute to the development, progression, and disposition of associated adverse health outcomes (Albertini et al. 2006; Angerer et al. 2007; Farmer et al. 1996, Needham et al. 2007).

One way to overcome sampling difficulties for biomonitoring is the use of samples collected for other purposes (Albertini et al. 2006). Blood spots, usually collected to look for a variety of adverse genetic conditions in newborns, are an efficient and unintrusive method to conduct heavy metal surveillance for that population (Olshan 2007).

**Pilot Biomonitoring Project:** One of the objectives for this project was to assess the feasibility of using blood spots as a mechanism for conducting public health surveillance for EBCLs in Utah newborn children (Funk et al. 2013; Olshan 2007).

The value of a public health surveillance system can be assessed by understanding the usability of the information derived through surveillance and the reliability and efficacy of the surveillance methodology. The usefulness of the information can be evaluated by understanding its scientific basis, relevance, and ability to be translated into public health actions or policy (Malecki et al. 2008). Analytical soundness is usually measured by statistical comparisons of the surveillance methodology with a gold standard in terms of sensitivity, specificity, and predictive value positive (German 2000).

The UPHL used commercially prepared venous blood containing a standardized concentration of cadmium (i.e., standard reference material) to spike blank blood spot papers that were included with each batch of newborn blood spots to assure quality of the laboratory analyses. Because the UPHL used commercially available standard reference material with known cadmium levels that was spiked on to filter paper and included those spiked filter papers as part of the quality control, there is certainty about the ability of the UPHL to accurately and consistently test blood spots (Chaudhuri et al. 2009). In addition, the UPHL successfully participated in the Wisconsin State Laboratory of Hygiene proficiency testing program for filter paper blood cadmium testing during the duration of this study, further demonstrating the utility and accuracy of the laboratory analytical method.
The laboratory specificity and sensitivity is the ability to accurately quantify the level of cadmium from the same blood spot punch demonstrated by multiple tests of that sample. Epidemiologists also use tests of specificity, sensitivity, and predictive value positive to quantify how well laboratory results correctly identify people with EBCLs and increased risk for adverse health outcomes. The data necessary to quantify the true epidemiologic specificity, sensitivity, and predictive value positive for this testing methodology were not available. Instead, the EEP used the test results for those samples where two or more different punches from the same card were analyzed. Using those data, the specificity was estimated to be 96%, which is an acceptable level. However, the predictive value positive was estimated to be 40%. This level suggests that the use of blood spots may not perform well as a screening test for children born with EBCLs. To know for certain, a different kind of study would need to be conducted that allowed the matching of blood spot results to serological tests for cadmium and to the children’s health status.

Typically, a surveillance system would be founded on one or more surveillance objectives, such as quantifying and characterizing the magnitude of public health concerns in a population at risk; obtaining increased understanding of the epidemiology of a public health concern; empowering sound, preventive or mitigating public health actions and policies; and evaluating those actions or policies. Justification for conducting surveillance requires balancing the costs, the collection of personal information, and the legal concerns against needs and strengths of the surveillance objectives. An effective surveillance system typically links laboratory analysis with additional data (Sneider and Stroup 2000; Stanbury et al. 2012; Teutsch 2000; Thacker et al. 1996; Thacker and Birkhead 2002).

This report presents data that attempt to quantify the magnitude of elevated blood cadmium in newborn children. However, there is insufficient data to fully characterize the health concern or understand the epidemiology involved with respect to probable risk factors. To be useful, these data would have to be linked to other data collected about the mother and her pregnancy. For example, it would be important to know what the historical and current exposures to cadmium are for the mother, and whether any of the current exposures can be mitigated.

Currently, there is no guidance on the testing and treatment of infants for blood cadmium, and there are few treatment options for newborns with EBCLs. Those options, such as chelation therapy, result in other health concerns and need to be used selectively (Bernhoft 2012). Preventive interventions, such as better choices regarding smoking, hand washing behaviors, and avoiding the use of cadmium-containing products, may reduce the mother’s BCLs and thus fetal exposure.

The findings of this investigation suggest that as many as 76 children could be born each year in Utah with EBCLs (≥5.00 µg/L). However, this finding is based on a testing methodology that has not been validated and does not appear to have good predictive power. In addition, there is no definition of elevated blood cadmium levels for children, and it is uncertain that an occupational standard would be relevant. Currently, Utah does not have a policy regarding screening for women of childbearing age for blood cadmium. While the results of this investigation are informative about the spatial distribution of the blood cadmium levels in Utah
children, these results do not indicate a need to establish an adult screening policy. The geometric mean cadmium level of 0.10 µg/L is below the national geometric mean level of 0.41 µg/L (CDC 2014). Adult testing and treatment should be guided by a clinical presentation that suggests a need (Bernhoft 2012).

This pilot project used de-identified data to examine the efficacy of using blood spots as a means of conducting noninvasive blood cadmium screening among newly born children in Utah. Because the children were not identified, the results for the two children with EBCLs were not reported to the health care provider or guardians of those children.

**Methodology Limitations**: The public often wants public health investigations to determine whether health risks can be linked to a putative environmental concern. The methods used in this investigation do not have the capability to definitively link the findings of elevated neonatal blood cadmium exposure risk to any inherent or external risk factors, including environmental exposures. This kind of investigation is sometimes referred to as a “snapshot,” and presents data about the health status of newly born children in Utah during 2009. A concern with “snapshot” investigations is that the data in this report may be used to generate inferences leading to public health policy or action based on this single assessment. The environmental risks associated with those counties where significant results were found should be assessed before any change to public health policy or program actions are made regarding cadmium poisoning in children (Meliker and Sloan 2011).

An investigation that uses population-based summary data rather than individual-level data, such as the investigation presented in this report, is called an ecologic study by epidemiologists. An interpretation error commonly associated with ecologic studies is to apply population-level risk findings to the individual. This kind of interpretation error is called an “ecologic fallacy.” For example, this study found the statewide risk for elevated blood cadmium among neonates was 1.42 per 1,000 births. This risk metric should not be applied to individuals. An individual may have no risk or a risk several times higher than the overall statewide risk (Greenland 2001; Greenland and Robins 1994; Morgenstern 1982, 1995; Rockhill 2005).

In this investigation, 47.5% (1,285 of 2,706) of the blood spot cards were found to be unusable for surveillance purposes because the measured level of cadmium in the paper blank was higher than the measured level of cadmium in the blood spot. This limitation is a significant barrier to consideration of using blood spots as a means of conducting population surveillance for cadmium exposure.

**CONCLUSIONS AND RECOMMENDATIONS**

This report provides a description and findings of a pilot surveillance project using newborn blood spots as a possible sampling media to conduct surveillance for heavy metal exposure. EBCLs in the developing fetus or newborn child can cause a number of adverse health effects, including harm to neurological and hematological development. There is no level of blood cadmium that is considered safe. This study found that approximately 1.42 newborns per 1,000 live births, or as many as 76 children per year (where the 2007-2012 average birth year cohort is
53,000 births), may have EBCLs at birth. However, this estimation is based on a testing methodology that has not been validated and statistical indications of performance were less than ideal. Utah does not currently have a policy regarding screening for women of childbearing age for cadmium exposure. The EEP does not recommend establishing a policy at this time.

Before neonatal blood spots can be used as a routine screening media, additional work would be needed to determine and improve the sensitivity, specificity, and predictive value positive of the testing methodology. BCL results using newborn blood spot samples would need to be validated using venous blood from the same newborn. In addition, prior to any decision on whether to or how to implement this testing methodology as part of Utah’s routine public health surveillance activities, consideration with respect to the need for routine blood cadmium surveillance in newborns, cost, alternative methods, and case follow-up should occur.
AUTHORSHIP, REVIEW AND CITATION

This report was prepared by:

Sam LeFevre
Environmental Epidemiology Program
Bureau of Epidemiology
Utah Department of Health

Mail: PO Box 142104, Salt Lake City, Utah 84114-2104
Street: 288 North 1460 West, Salt Lake City, Utah 84116
Phone: (801) 538-6191
Fax: (801) 538-6564
Email: slefevre@utah.gov

Contributors:

Sanwat N Chadhuri, PhD, Scientific Advisor, Chemical and Environmental Laboratory, Utah Public Health Laboratories
Jason Barnes, Chemist
Merril Chipman, Chemist
Robyn Atkinson-Dunn, PhD, Director, Utah Public Health Laboratories
Kim Hart, MS, LCGC, Manager, Newborn Screening Program
B Gregory Williams, MPH, CPM, Manager, Utah Environmental Public Health Tracking Network

Certifying Reviewers:

Allyn K Nakashima, MD, State Epidemiologist
Cristie Chesler, Director, Bureau of Epidemiology
Wu Xu, PhD, Director, Center for Health Data and Informatics

Recommended Citation:

CERTIFICATION

This report titled “Utah Statewide Investigation of Neonatal Blood Cadmium Levels Using Newborn Blood Spot Specimens” was prepared by the Environmental Epidemiology Program, Utah Department of Health. This report describes the findings of a pilot surveillance project using newborn blood spots as a medium for conducting blood cadmium surveillance. Editorial and technical review was completed by UDOH certifying reviewers and program partners.

Approved by:

Cristie Chesler  
Director, Bureau of Epidemiology  
Utah Department of Health

Allyn K Nakashima, MD  
State Epidemiologist  
Utah Department of Health

Wu Xu, PhD  
Director, Center for Health Data and Informatics  
Utah Department of Health
REFERENCES

Web links for citations of government or organizational websites may wrap onto multiple lines.


Kutlu T, Karagozler AA, Gozukara EM. 2006. Relationship among placental cadmium, lead, zinc, and copper levels in smoking pregnant women. *Biological Trace Element Research* 114(1-3)7-17.


Wilhelm M, Schulz C, Schwenk M. 2006. Revised and new reference values for arsenic, cadmium, lead, and mercury in blood or urine of children: basis for validation of human
biomonitoring data in environmental medicine. *International Journal of Hygiene and Environmental Health* 209(3):301-305.
TABLES AND FIGURES


<table>
<thead>
<tr>
<th>Sex</th>
<th>Total Births Statewide</th>
<th>Samples Tested</th>
<th>Geometric Mean Blood Cadmium Level µg/L (95% confidence limit)</th>
<th>Highest Observed Blood Cadmium Level µg/L</th>
<th>Number Tests with Blood Cadmium Levels Greater than 5.0 µg/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female</td>
<td>26,264</td>
<td>686</td>
<td>0.11 (0.03 – 0.18)</td>
<td>8.64</td>
<td>1</td>
</tr>
<tr>
<td>Male</td>
<td>27,486</td>
<td>718</td>
<td>0.10 (0.02 – 0.17)</td>
<td>6.91</td>
<td>1</td>
</tr>
<tr>
<td>Both</td>
<td>53,750</td>
<td>1,404</td>
<td>0.10 (0.05 – 0.15)</td>
<td>8.64</td>
<td>2</td>
</tr>
</tbody>
</table>
FIGURE 1. Geometric mean blood cadmium levels by county in Utah among children born in 2009. “C” is the number of newborn children tested in each county. “GM” is the geometric mean blood cadmium level in µg/L. These findings are based on maternal residential address at the time of birth.
TABLE 2. Summary of Utah neonatal blood cadmium levels by county for children born in 2009. These data are based on the maternal residential address at the time of birth.

<table>
<thead>
<tr>
<th>County</th>
<th>Total Births Statewide</th>
<th>Samples Tested</th>
<th>Geometric Mean Blood Cadmium Level µg/L (95% confidence level)</th>
<th>Highest Observed Blood Cadmium Level µg/L</th>
<th>Number Tests with Blood Cadmium Levels Greater than 5.0 µg/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beaver</td>
<td>131</td>
<td>1</td>
<td>0.13 (----- – -----)</td>
<td>0.13</td>
<td>0</td>
</tr>
<tr>
<td>Box Elder</td>
<td>992</td>
<td>32</td>
<td>0.12 (0.00 – 0.48)</td>
<td>0.60</td>
<td>0</td>
</tr>
<tr>
<td>Cache</td>
<td>2,520</td>
<td>65</td>
<td>0.09 (0.00 – 0.34)</td>
<td>1.22</td>
<td>0</td>
</tr>
<tr>
<td>Carbon</td>
<td>320</td>
<td>16</td>
<td>0.09 (0.00 – 0.64)</td>
<td>1.31</td>
<td>0</td>
</tr>
<tr>
<td>Daggett</td>
<td>12</td>
<td>2</td>
<td>0.11 (0.00 – 1.62)</td>
<td>0.13</td>
<td>0</td>
</tr>
<tr>
<td>Davis</td>
<td>6,041</td>
<td>162</td>
<td>0.11 (0.00 – 0.27)</td>
<td>1.31</td>
<td>0</td>
</tr>
<tr>
<td>Duchesne</td>
<td>300</td>
<td>7</td>
<td>0.22 (0.00 – 1.16)</td>
<td>8.64</td>
<td>1</td>
</tr>
<tr>
<td>Emery</td>
<td>187</td>
<td>3</td>
<td>0.07 (0.00 – 1.64)</td>
<td>0.21</td>
<td>0</td>
</tr>
<tr>
<td>Garfield</td>
<td>58</td>
<td>3</td>
<td>0.02 (0.00 – 1.38)</td>
<td>0.04</td>
<td>0</td>
</tr>
<tr>
<td>Grand</td>
<td>129</td>
<td>39</td>
<td>0.15 (0.00 – 0.48)</td>
<td>6.91</td>
<td>1</td>
</tr>
<tr>
<td>Iron</td>
<td>887</td>
<td>20</td>
<td>0.09 (0.00 – 0.56)</td>
<td>1.76</td>
<td>0</td>
</tr>
<tr>
<td>Juab</td>
<td>242</td>
<td>5</td>
<td>0.09 (0.00 – 1.16)</td>
<td>0.29</td>
<td>0</td>
</tr>
<tr>
<td>Kane</td>
<td>83</td>
<td>4</td>
<td>0.04 (0.00 – 1.21)</td>
<td>0.10</td>
<td>0</td>
</tr>
<tr>
<td>Millard</td>
<td>219</td>
<td>4</td>
<td>0.09 (0.00 – 1.36)</td>
<td>0.38</td>
<td>0</td>
</tr>
<tr>
<td>Morgan</td>
<td>210</td>
<td>5</td>
<td>0.03 (0.00 – 1.31)</td>
<td>0.09</td>
<td>0</td>
</tr>
<tr>
<td>Piute</td>
<td>26</td>
<td>4</td>
<td>0.07 (0.00 – 1.69)</td>
<td>0.33</td>
<td>0</td>
</tr>
<tr>
<td>Rich</td>
<td>42</td>
<td>2</td>
<td>0.15 (0.00 – 3.94)</td>
<td>0.60</td>
<td>0</td>
</tr>
<tr>
<td>Salt Lake</td>
<td>18,664</td>
<td>448</td>
<td>0.11 (0.02 – 0.21)</td>
<td>2.88</td>
<td>0</td>
</tr>
<tr>
<td>San Juan</td>
<td>200</td>
<td>17</td>
<td>0.13 (0.00 – 0.63)</td>
<td>2.15</td>
<td>0</td>
</tr>
<tr>
<td>Sanpete</td>
<td>363</td>
<td>11</td>
<td>0.20 (0.00 – 0.84)</td>
<td>0.70</td>
<td>0</td>
</tr>
<tr>
<td>Sevier</td>
<td>361</td>
<td>7</td>
<td>0.07 (0.00 – 0.87)</td>
<td>0.17</td>
<td>0</td>
</tr>
<tr>
<td>Summit</td>
<td>536</td>
<td>16</td>
<td>0.06 (0.00 – 0.61)</td>
<td>1.28</td>
<td>0</td>
</tr>
<tr>
<td>Tooele</td>
<td>1,033</td>
<td>21</td>
<td>0.15 (0.00 – 0.61)</td>
<td>0.91</td>
<td>0</td>
</tr>
<tr>
<td>Uintah</td>
<td>845</td>
<td>22</td>
<td>0.08 (0.00 – 0.52)</td>
<td>0.85</td>
<td>0</td>
</tr>
<tr>
<td>Utah</td>
<td>12,231</td>
<td>304</td>
<td>0.09 (0.00 – 0.20)</td>
<td>3.90</td>
<td>0</td>
</tr>
<tr>
<td>Wasatch</td>
<td>414</td>
<td>5</td>
<td>0.22 (0.00 – 1.36)</td>
<td>1.64</td>
<td>0</td>
</tr>
<tr>
<td>Washington</td>
<td>2,440</td>
<td>58</td>
<td>0.10 (0.00 – 0.37)</td>
<td>2.37</td>
<td>0</td>
</tr>
<tr>
<td>Wayne</td>
<td>26</td>
<td>0</td>
<td>----- (----- – -----)</td>
<td>-----</td>
<td>0</td>
</tr>
<tr>
<td>Weber</td>
<td>4,238</td>
<td>121</td>
<td>0.08 (0.00 – 0.26)</td>
<td>4.32</td>
<td>0</td>
</tr>
</tbody>
</table>
DEFINITIONS

**ArcGIS**: A computer application that provides mapping and spatial analysis of spatially referenced data. ArcGIS is a product developed and available through ESRI. For more information see: http://www.esri.com or http://www.arcgis.com.

**Biomonitoring**: A way of measuring which substances humans have been exposed to and the level of exposure to those compounds, through analysis of body fluids (e.g., saliva, urine, or blood, etc.) or tissues (e.g., epithelial cells obtained by swabbing the mouth, or hair, or nail clippings, etc.) for those compounds or metabolites of those compounds.

**Blood Spots**: Drops of blood placed on a filter card and dried. Blood spot cards are prepared for infants by sampling the blood obtained by a heel stick.

![](image)

**BCL**: Blood cadmium level. The amount of cadmium in the blood, quantified as micrograms of cadmium per liter of blood (µg/L). Blood cadmium levels greater than or equal to 5.0 µg/L are considered elevated based on the current EPA reference dose.

**CDC**: Centers for Disease Control and Prevention. A federal agency within the U.S. Department of Health and Human Services responsible for investigating disease trends and causalities, and promoting best disease prevention practices. For more information see: http://www.cdc.gov/.

**EBCL**: Elevated blood cadmium levels. Blood cadmium levels greater than or equal to 5.0 µg/L are considered elevated based on the current EPA reference dose.

**EEP**: Environmental Epidemiology Program. A program within the Bureau of Epidemiology, Division of Disease Control and Prevention, UDOH. The EEP was established in 1996 and is responsible for investigating diseases related to the environment. The program has two sections. One section conducts surveillance and data management activities, including managing the UEPHTN. The other section conducts health hazards risk assessment, including cancer investigations. The program is staffed by personnel with experience and expertise in environmental epidemiology, environmental sciences, toxicology, statistics, public health informatics and geomatics, and health education. For more information see: http://health.utah.gov/enviroepi/.
**EPA**: U.S. Environmental Protection Agency. The EPA is responsible for investigating environmental pollution and health hazards. For more information see: http://www.epa.gov/.

**ESRI**: ESRI (formally known as Environmental Systems Research Institute) is a leading developer and supplier of GIS software and geographically referenced data. ESRI is headquartered in Redlands, California. The EEP uses the ArcGIS software application developed by ESRI. For more information see: http://www.esri.com.

**Geometric mean**: A type of average or measurement of central tendency that uses the products of a set of numbers rather than the summation. The geometric mean of a data set \{a_1, a_2, ..., a_n\} is given by \((\Pi a_i)^{1/n}\). The geometric mean is used to describe the average of blood cadmium levels because the distribution of values in the data set is skewed towards zero, and no value can be less than zero.

**GIS**: Geographic Information Systems. A GIS includes computer software and geographically referenced data. The EEP uses ArcGIS as the computer software and obtains data from ESRI or AGRC.

**ICP-MS**: Inductively coupled plasma mass spectrometry. This is a laboratory methodology that is able to separate and quantify the amount of atoms or compounds present in a solution based on the mass of those atoms or compounds.

**RMBC**: Rocky Mountain Biomonitoring Consortium. The RMBC was a CDC-funded collaboration of the state laboratories of Arizona, Colorado, Montana, New Mexico, Utah, and Wyoming. The New Mexico Scientific Laboratory served as the grant coordinating laboratory and distributed funds from CDC to the other states within the consortium. Each state laboratory developed one or more biomonitoring analytical capabilities that could serve the needs of all of the states biomonitoring needs. Utah developed methodology for blood spot testing for heavy metals.

**SAS**: SAS (originally from “Statistical Analysis System”) is a globally recognized system of integrated computer software products provided by SAS Institute Inc. The SAS system includes a large variety of data manipulation and statistical analysis processes. The EEP uses the desktop version 9.2. For more information see: http://www.sas.com.

**UDOH**: Utah Department of Health. The UDOH is one of the executive agencies within Utah state government. The UDOH strives to improve health in Utah by promoting healthy lifestyles, evidence-based interventions, creating healthy and safe communities, and eliminating health disparities. The EEP is a program within the UDOH. For more information, see: http://health.utah.gov/.
UEPHTN: Utah Environmental Public Health Tracking Network. The UEPHTN is a data warehouse that contains health outcomes, environmental, and supporting data. For more information see: http://epht.health.utah.gov/epht-view/.

µg/L: Micrograms per liter. A microgram is one millionth of a gram.

UPHL: Utah Public Health Laboratory. A part of the Unified State Laboratories. The UPHL provides laboratory support to other state agencies and to the public. For more information, see: http://health.utah.gov/lab/index.html.
DESCRIPTION OF THE LABORATORY METHODOLOGY

Preparation of Samples and Internal Blanks: Filter paper punches, each ¼ inch (6.35 mm) in diameter, were punched from cards containing newborn dried blood spots directly into 15 mL polypropylene tubes (Stockwell Scientific #3220N, Scottsdale, Arizona). Two sets of dots (in duplicate) were punched. The first set was comprised of two dots from the card adjacent to the newborn’s blood sample spots and is defined as the internal blank. The internal blank dots were assumed to have been exposed to the same environmental conditions as the actual blood samples and hence are utilized to assess extraneous environmental contamination from the hospital, contamination during transit to the laboratory, storage contamination, and contamination during laboratory handling. The second set of dots was comprised of two dots punched directly from the dried blood spots. An empty 15 mL polypropylene tube from the same lot as the other tubes was utilized as a control tube. This “blank” tube was filled with the same extraction solution as the tubes containing the actual samples and carried throughout the entire extraction procedure to assess contamination from the actual procedure.

The dots were extracted with a 2% hydrochloric acid solution (GFS Chemicals®, Columbus, Ohio) containing 0.05% 2-mercaptoethanol (Acros Organics, Thermo Fisher Scientific #12547-2500), 0.001% l-cysteine (Fluka, Milwaukee, Wisconsin), and 10 µg/L iridium and rhodium (Spex Industries Inc., Edison, New Jersey). The latter two elements served as internal standards. 1.5 mL of the extraction solution was added to each tube and then vortexed for 15 minutes. The tubes were then allowed to stand overnight (about 16-18 hours), then vortexed for another 15 minutes, and lastly, centrifuged for 5 minutes at 5,000 RPM in an Eppendorf 5804 centrifuge (Brinkman Instruments, Inc., Westbury New York). The tubes were then placed into the autosampler of the inductive coupled plasma mass spectrometer (ICP-MS) for analysis.

Quality Control and Quality Assurance: With each batch of blood spot samples (typically ten spots), the following quality control samples were analyzed at a minimum: a set of calibration standards; a blank control (negative) to assure the system is free of contamination from previous analyses; a positive control using commercially prepared standard reference material (SRM) to assess accuracy; and a set of duplicate samples to assess precision. The SRM samples were prepared from a freeze-dried human whole blood toxicology control (whole blood control lots 7984 and 8083) that were custom made for low level cadmium and other heavy metals by Utak Laboratories, Inc. (Valencia, California). The material had a known, verified mean cadmium concentration and an expected analytical range. The material was reconstituted by adding 3 mL of 18 megaohm water with a volumetric pipette. The mixture was gently swirled for 5-10 minutes then allowed to stand for 1 hour for equilibration and subsequent warming to room temperature. The reconstituted blood was then spotted drop-wise with a Pasture pipette onto S&S (Keene, New Hampshire) 903, lot W011 filter paper. The blood was added until the dotted, printed circle was filled, which corresponds to a total blood volume of about 75 µL (CLSI 2007). This has also been calibrated during the present study. The spotted filter paper cards were dried
for several hours then placed in TearZone Safeguard Specimen bags, stored under refrigerated conditions, and analyzed in the same manner as patient samples.

The calibration curve was constructed using aqueous-based samples and calculated using ordinary linear regression methods. Weighting was not used and the intercepts were not forced through the origin.

Additional quality assurance was demonstrated by the UPHL’s participation in the Wisconsin State Laboratory of Hygiene proficiency test program for filter paper blood analysis during the duration of this study. Every testing event was passed.

**Analysis:** The samples were analyzed utilizing ICP-MS. An Elan DRC II ICP-MS machine (PerkinElmer, Shelton, Connecticut) equipped with a Meinhard nebulizer and a quartz cyclonic spray chamber was used to make these readings. The dynamic reaction cell (DRC) was not utilized for this work. For cadmium, the three isotopes scanned and summed were m/z 111. No significant inference was observed at this m/z. Arithmetic isobaric correction equations were utilized and two replicate readings were taken for each m/z.

For a more detailed description of the methods briefly described here, see Chaudhuri et al. 2009.